NCT07309900

IASO208 Injection in the Treatment of Relapsed/Refractory B-cell Malignancies

A Single-arm, Open-label Exploratory Clinical Study of IASO208 Injection in the Treatment of Relapsed/Refractory B-cell Malignancies

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 12 (estimated)
• Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is an investigator-initiated, single-arm, open-label clinical study. It employs a dose-escalation design to evaluate the safety, pharmacokinetics, and preliminary efficacy of IASO208 injection in relapsed/refractory B-cell malignancies.

Conditions

• Relapsed/Refractory B-cell Malignancies

Interventions

Type	Name	Description
GENETIC	IASO208 injection	IASO208 injection is a third-generation, self-inactivated, replication-deficient Lentiviral Vector (LVV) gene therapy research drug.

Timeline

• Start date: 2025-11-21
• Primary completion: 2028-12-15
• Completion: 2029-06-15
• First posted: 2025-12-30
• Last updated: 2026-01-12

Locations

1 site across 1 country: China